Related Experiment Videos
Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11
Shigenobu Matsuzaki1, Masaharu Yasuda, Hiroshi Nishikawa
1Department of Microbiology, Kochi Medical School, Kochi, Japan.
Abstract:
The protective effects of bacteriophages were assessed against experimental Staphylococcus aureus infection in mice. Of the S. aureus phages isolated in the study, phi MR11 was representatively used for all testing, because its host range was the most broad and it carries no genes for known toxins or antibiotic resistance. Intraperitoneal injections (8 x 10(8) cells) of S. aureus, including methicillin-resistant bacteria, caused bacteremia and eventual death in mice. In contrast, subsequent intraperitoneal administration of purified phi MR11 (MOI > or = 0.1) suppressed S. aureus-induced lethality. This lifesaving effect coincided with the rapid appearance of phi MR11 in the circulation, which remained at substantial levels until the bacteria were eradicated. Inoculation with high-dose phi MR11 alone produced no adverse effects attributable to the phage. These results uphold the efficacy of phage therapy against pernicious S. aureus infections in humans and suggest that phi MR11 may be a potential prototype for gene-modified, advanced therapeutic S. aureus phages.
Insights
Bacteriophage therapy using phi MR11 effectively protected mice against lethal Staphylococcus aureus infections. This phage therapy suppressed bacterial growth and prevented mortality, showing promise for treating S. aureus infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Bacteriophage Therapy
Background:
- Staphylococcus aureus, including methicillin-resistant strains, causes severe infections.
- Bacteriophages are viruses that infect bacteria and are being explored as an alternative therapy.
Purpose of the Study:
- To evaluate the protective efficacy of bacteriophage phi MR11 against experimental Staphylococcus aureus infection in mice.
- To assess the safety and pharmacokinetics of phi MR11 in vivo.
Main Methods:
- Mice were infected with Staphylococcus aureus.
- Therapeutic administration of purified bacteriophage phi MR11 was performed.
- Lethality, bacteremia, and phage presence in circulation were monitored.
Main Results:
- Intraperitoneal administration of phi MR11 significantly suppressed S. aureus-induced lethality in mice.
- Phi MR11 rapidly appeared in circulation and persisted until bacterial eradication.
- High-dose phi MR11 administration alone showed no adverse effects.
Conclusions:
- Bacteriophage therapy with phi MR11 is effective against Staphylococcus aureus infections in a murine model.
- Phi MR11 demonstrates potential as a prototype for developing advanced phage therapies against S. aureus.
- Phage therapy offers a promising strategy for combating pernicious S. aureus infections.